| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that Jarrod Longcor, chief operating officer of Cellectar, presented positive preclinical data in a poster at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research that took place from September 28 through October 1, 2025, in Boston, Massachusetts. The poster highlighted preclinical data from CLR 121225 (CLR 225), the Company's novel actinium-based radio conjugate alpha-emitter for treatment in pancreatic ductal adenocarcinoma (PDAC). CLR 225 has completed Investigational New Drug (IND)-enabling studies, and the company maintains the option to advance into a Phase 1 study.
"We were honored to present these preclinical data before a distinguished audience of oncology professionals. The novel mechanism of action of our phospholipid ethers may enable us to more effectively target and eradicate diverse tumor cell populations and, importantly, penetrate the dense, collagen-rich extracellular matrix that characterizes pancreatic cancer. By overcoming this major barrier to therapeutic delivery, we hope to address one of the fundamental reasons pancreatic tumors remain so refractory to standard treatments and ultimately improve patient outcomes," said Jarrod Longcor, chief operating officer of Cellectar. "These results showcase the robust anti-tumor activity, selective biodistribution, and impressive uptake of CLR 225 in multiple pancreatic cancer tumor models. The data strongly support the therapeutic potential of CLR 225."
A series of studies evaluated three separate pancreatic cancer xenograft models (PANC-1, MIA PaCa-2 human pancreatic carcinoma cells and BxPC-3 tumor fragments) treated with CLR 225 at multiple doses. CLR 225 was deemed safe and well-tolerated at all dosing levels with no changes in body weight or loss of animals. Notably, all three xenograft models treated with CLR 225 demonstrated either meaningful inhibition of tumor growth or reduction in tumor volume, depending on the dose, with potential survival benefit following treatment as tumor growth post treatment was significantly diminished.
Additional pharmacokinetic studies showed excellent biodistribution of CLR 225, indicating predictable behavior with dose linearity, which can assist with future estimation of a likely efficacious dose. Furthermore, in preparation for Phase 1 first-in-human studies, the poster presented data on CLR 225 in various GLP toxicity studies where no toxicities to the compound were noted.
Posted In: CLRB
